SCPH SCPharmaceuticals Inc

scPharmaceuticals to Announce First Quarter 2025 Financial Results After the Market Close on May 14, 2025

scPharmaceuticals to Announce First Quarter 2025 Financial Results After the Market Close on May 14, 2025

Management to host conference call and webcast, after-market on May 14, 2025, at 4:30 p.m. ET

BURLINGTON, Mass., May 07, 2025 (GLOBE NEWSWIRE) -- scPharmaceuticals Inc. (Nasdaq: SCPH), a pharmaceutical company committed to revolutionizing cardiorenal healthcare through patient-centric innovations, today announced that scPharmaceuticals management will host a conference call and audio webcast at 4:30 p.m. ET on Wednesday, May 14, 2025, to discuss the financial results for the first quarter 2025 and provide a business update.

Registration and access for the conference call can be completed through this

The live webcast and replay of the conference call can be accessed or under “News & Events” in the Investor Relations section of the Company’s website, .

About scPharmaceuticals

At scPharmaceuticals, we are powered by passion, driven by patient care. Our Mission is focused on advancing cardiorenal care through innovative, integrated treatments that address unmet patient needs.

Our goal is to become the foremost advocate for patient-centric cardiorenal care, driving global health improvements through specialized, multidisciplinary approaches. scPharmaceuticals is expanding its reach, offering integrated therapies and products that address diverse healthcare needs and potentially improve the lives of our patients. scPharmaceuticals is headquartered in Burlington, MA. For more information, please visit .

Katherine Miranda

scPharmaceuticals Inc., (781) 301-6869

Investors:

Matthew Beck

astr partners, (917) 415-1750



EN
07/05/2025

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on SCPharmaceuticals Inc

 PRESS RELEASE

scPharmaceuticals to Announce First Quarter 2025 Financial Results Aft...

scPharmaceuticals to Announce First Quarter 2025 Financial Results After the Market Close on May 14, 2025 Management to host conference call and webcast, after-market on May 14, 2025, at 4:30 p.m. ET BURLINGTON, Mass., May 07, 2025 (GLOBE NEWSWIRE) -- scPharmaceuticals Inc. (Nasdaq: SCPH), a pharmaceutical company committed to revolutionizing cardiorenal healthcare through patient-centric innovations, today announced that scPharmaceuticals management will host a conference call and audio webcast at 4:30 p.m. ET on Wednesday, May 14, 2025, to discuss the financial results for the first q...

 PRESS RELEASE

scPharmaceuticals Announces Participation in Three Upcoming Investor C...

scPharmaceuticals Announces Participation in Three Upcoming Investor Conferences BURLINGTON, Mass., May 01, 2025 (GLOBE NEWSWIRE) -- scPharmaceuticals Inc. (Nasdaq: SCPH) (the “Company”), a pharmaceutical company committed to revolutionizing cardiorenal healthcare through patient-centric innovations, today announced that John Tucker, President and Chief Executive Officer, will participate in the following upcoming investor conferences: The Citizens Life Sciences Conference: Presentation on Wednesday, May 7 at 9:30 a.m. ET.Craig-Hallum 22nd Annual Institutional Investor Conference: We...

 PRESS RELEASE

scPharmaceuticals Inc. Reports Fourth Quarter and Full Year 2024 Finan...

scPharmaceuticals Inc. Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update scPharmaceuticals generated fourth quarter 2024 net FUROSCIX® revenue of $12.2 million, and full year 2024 revenue of $36.3 million Cash and cash equivalents of $75.7 million as of December 31, 2024 U.S. Food and Drug Administration (FDA) approved the FUROSCIX expanded label indication to include the treatment of edema due to fluid overload in patients with chronic kidney disease scPharmaceuticals to host investor conference call and webcast today, Wednesday, March 19th,...

 PRESS RELEASE

scPharmaceuticals to Announce Fourth Quarter and Full Year 2024 Financ...

scPharmaceuticals to Announce Fourth Quarter and Full Year 2024 Financial Results on Wednesday, March 19, 2025 Management to host conference call and webcast, after-market on March 19, 2025, at 4:30 p.m. ET BURLINGTON, Mass., March 12, 2025 (GLOBE NEWSWIRE) -- scPharmaceuticals Inc. (Nasdaq: SCPH), a pharmaceutical company committed to revolutionizing cardiorenal healthcare through patient-centric innovations, today announced that scPharmaceuticals management will host a conference call and audio webcast at 4:30 p.m. ET on Wednesday, March 19, 2025, to discuss the financial results for ...

 PRESS RELEASE

scPharmaceuticals Announces FDA Approval of Supplemental New Drug Appl...

scPharmaceuticals Announces FDA Approval of Supplemental New Drug Application Expanding the FUROSCIX® Indication to Include the Treatment of Edema in Patients with Chronic Kidney Disease FDA approves scPharmaceuticals’ supplemental New Drug Application to expand the FUROSCIX indication to include the treatment of edema in adult patients with chronic kidney disease, including nephrotic syndrome FUROSCIX is expected to be available for chronic kidney disease patients in April 2025 BURLINGTON, Mass., March 06, 2025 (GLOBE NEWSWIRE) -- scPharmaceuticals Inc. (Nasdaq: SCPH) (the “Company”), ...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch